Rapid Serodiagnostics Platform for PoC

Invention: Molecular biology assays to accurately and quickly measure immunoglobulins from serum.
Indications: Infectious diseases, autoimmune diseases, allergy.
Unmet need: Reliable and rapid serodiagnostics in Point-of-Care are lacking.
IP Status: Patent pending.
Project status: Proof-of-concept for Puumala Virus, Zika Virus and Coeliac Disease.

Save as PDF

Novel molecular tools for rapid infectious disease diagnostics are constantly under development to reduce the time between onset of symptoms and diagnosis. Not only is it important to receive appropriate treatment, but also to avoid unnecessary use of antibiotics. The availability of rapid diagnostics is also important when epidemics or pandemics emerge. Although rapid, current point-of-care (POC) tests offer suboptimal sensitivity and specificity. We have applied a novel patented invention to develop immunoassays with sensitivity and specificity rates approaching those of conventional reference tests. Our invention is applicable not only in infectious disease diagnosis, but also in diagnosis of autoimmune diseases and allergies – basically in any disease that can be serodiagnosed. The first applications of our invention are for autoimmune (coeliac disease) and infectious diseases (Zika virus and hantavirus infections).

Satu Hepojoki
Clinicum, Faculty of Medicine, University of Helsinki

Granted EP 3111218 and other national patent applications pending.

Hepojoki, S. et al., 2015. Rapid homogeneous immunoassay based on time-resolved Förster resonance energy transfer for serodiagnosis of acute hantavirus infection. G. A. Land, ed. Journal of clinical microbiology.